ArticleCancers2022
Implementing Risk-Stratified Breast Screening in England: An Agenda Setting Meeting.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- "For and against" factors influencing participation in personalized breast cancer screening programs: a qualitative systematic review until March 2022.Archives of public health = Archives belges de sante publique · 2024Pooled it
- Acceptability of de-intensified screening for women at low risk of breast cancer: a randomised online experimental survey.BMC cancer · 2024Trial
- 'We know what the barriers are, but nothing changes' - Professional perspectives on promoting breast cancer screening initiatives for ethnic minority women.BMC health services research · 2026Article
- Scoring System for Predicting Breast Cancer Risk Among Women in Regions with Limited Healthcare Infrastructure in Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Performance of different polygenic risk scores for breast cancer risk prediction: in-depth evaluations across large UK and Australian cohorts.European journal of human genetics : EJHG · 2026Article
- Illness risk representations underlying women's breast cancer risk appraisals: A theory-informed qualitative analysis.British journal of health psychology · 2025Article
- Genetic discrimination in insurance and employment based on personalized risk stratification for breast cancer screening.Frontiers in genetics · 2025Article
- Cost-Effectiveness of AI for Risk-Stratified Breast Cancer Screening.JAMA network open · 2024Article
- A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening.Applied health economics and health policy · 2024Article
- The acceptability and clinical impact of using polygenic scores for risk-estimation of common cancers in primary care: a systematic review.Journal of community genetics · 2024Review
- Article
- Implementation considerations for risk-tailored cancer screening in the population: A scoping review.Preventive medicine · 2024Article
- A cost-effectiveness analysis of lung cancer screening with low-dose computed tomography and a polygenic risk score.BMC cancer · 2024Article
- What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study.British journal of cancer · 2023Article
- Tamoxifen evolution.British journal of cancer · 2023Review
- Promote Community Engagement in Participatory Research for Improving Breast Cancer Prevention: The P.I.N.K. Study Framework.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
It is now possible to accurately assess breast cancer risk at routine NHS Breast Screening Programme (NHSBSP) appointments, provide risk feedback and offer risk management strategies to women at higher risk. These strategies include National Institute for Health and Care Excellence (NICE) approved additional breast screening and risk-reducing medication. However, the NHSBSP invites nearly all women three-yearly, regardless of risk. In March 2022, a one-day agenda setting meeting took place in Manchester to discuss the feasibility and desirability of implementation of risk-stratified screening in the NHSBSP. Fifty-eight individuals participated (38 face-to-face, 20 virtual) with relevant expertise from academic, clinical and/or policy-making perspectives. Key findings were presented from the PROCAS2 NIHR programme grant regarding feasibility of risk-stratified screening in the NHSBSP. Participants discussed key uncertainties in seven groups, followed by a plenary session. Discussions were audio-recorded and thematically analysed to produce descriptive themes. Five themes were developed: (i) risk and health economic modelling; (ii) health inequalities and communication with women; (iii); extending screening intervals for low-risk women; (iv) integration with existing NHSBSP; and (v) potential new service models. Most attendees expected some form of risk-stratified breast screening to be implemented in England and collectively identified key issues to be resolved to facilitate this.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.